Pharma Mirror

MARCH 29, 2022

NIEL, BELGIUM, eTheRNA Manufacturing, a specialist RNA process developer and manufacturing member of the Belgian eTheRNA group, is introducing a new Lipid Nanoparticle (LNP) formulation development and production service to support the discovery and early pre-clinical development of RNA-based therapeutics and vaccines.

Manufacturing 130

Manufacturing Production Development RNA 130

Pharmaceutical Technology

AUGUST 21, 2022

An RNA-dependent RNA polymerase (RdRp) inhibitor, ASC10 is an oral double prodrug. Currently, the company is working with various regulatory agencies to explore the potential to further advance ASC10’s clinical development. Compared to molnupiravir, a single prodrug, ASC10 has a varied chemical structure.

In-Vivo 162

In-Vivo RNA Clinical Development Drugs 162

pharmaphorum

OCTOBER 18, 2021

SMi Group’s 13th Annual Conference: RNA Therapeutics 2022. Bolstering the latest advances and opportunities in RNA-based medicine. Delve into the latest innovations in novel RNA delivery and target specificity. Engage in the growing advances and development of RNA tools for vaccines and anti-infectives. London, UK.

RNA 52

RNA Drug Delivery Scientist Clinical Development 52

Outsourcing Pharma

JUNE 6, 2023

The development of small molecule antivirals that target viral RNA in Henipaviruses will benefit from a $1.7million grant from Open Philanthropy, a philanthropic funder prioritizing global health and wellbeing.

RNA 78

RNA Development Clinical Development 78

pharmaphorum

SEPTEMBER 1, 2020

The world of drug discovery and chemical probes is still protein-centric and developing highly selective small molecules targeting RNA is often considered to be an insurmountable challenge. Why You Should Attend the RNA- Targeted Drug Discovery Summit. The post 3rd RNA-Targeted Drug Discovery Summit appeared first on.

RNA 52

RNA Drugs Protein Clinical Development 52

Pharmaceutical Technology

MAY 19, 2023

Myeloid Therapeutics has raised $73m to support the continued clinical development of its lead cell therapy programme, MT-101, in Phase I/II trials for T cell lymphoma. The financing will help to fast-track the development of other in vivo programming candidates into clinical trials.

In-Vivo 246

In-Vivo Gene Therapy Gene RNA 246

pharmaphorum

SEPTEMBER 28, 2021

The 4th RNA-Targeted Drug Discovery Summit is returning once again this December, to reunite the largest community of thought leaders and experts in biology, chemistry and RNA therapeutics to discuss cutting-edge small molecule strategies capable of interacting with and modulating RNA with improved specificity, selectivity and drug-like properties.

RNA 52

RNA Drugs Clinical Development Development 52

Camargo

JULY 27, 2021

When developing a clinical development program for these increasingly popular therapies, it is important that sponsors use modeling and pharmacokinetic (PK) analysis to evaluate parameters that can be measured while dosing with gene therapy drugs, to characterize exposure-response data and inform rational dosing.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

BioSpace

AUGUST 24, 2021

Funds will be used to advance the clinical development of Cardior’s lead program, CDR132L, an oligonucleotide-based ncRNA inhibitor targeting micro-RNA-132.

RNA 75

RNA Clinical Development Development 75

BioTech 365

OCTOBER 14, 2020

DUBLIN–(BUSINESS WIRE)–The “RNA Therapies in Oncology: Analytical Tool” report has been added to ResearchAndMarkets.com’s offering.

RNA 40

RNA Business Development Clinical Development Development 40

Outsourcing Pharma

JANUARY 17, 2023

SanegeneBio has formed a service agreement with Orbit Discovery to support tissue-specific delivery of a wide range of RNA therapeutics.

RNA 52

RNA Clinical Development Development 52

pharmaphorum

SEPTEMBER 23, 2020

Programmable Oligonucleotide Delivery System (PODS), developed by Sixfold Bioscience, is a versatile system which delivers short interfering RNA (siRNA) gene silencing cargo to specific cancer cells.

Drug Delivery Systems 141

Drug Delivery Systems Gene Silencing Drug Delivery Medicine 141

pharmaphorum

OCTOBER 5, 2022

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. billion deal in 2018. The aim will be to identify promising candidates in areas of “unmet patient need.”

RNA 105

RNA Genetics Dermatology Antibody 105

BioTech 365

AUGUST 25, 2021

Cardior Raises €64M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease Cardior Raises €64M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease Oversubscribed round enables late-stage clinical development of lead … Continue reading →

RNA 40

RNA Clinical Development Development 40

Roots Analysis

OCTOBER 30, 2023

In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.

RNA 40

RNA Vaccination Vaccine Development 40

BioTech 365

SEPTEMBER 10, 2020

Funding, led by aMoon, will advance the clinical development of MiNA’s new class of RNA therapeutics for cancer treatment, and further expand its R&D pipeline in additional disease areas LONDON–(BUSINESS WIRE)–MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today … Continue reading →

RNA 40

RNA Clinical Development Development 40

Pharmaceutical Technology

JUNE 6, 2023

The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. MRNA-0184 Overview mRNA-0184 is under development for the treatment decompensated heart failure. The therapeutic candidate consists of messenger RNA (mRNA) encoding for relaxin.

RNA 100

RNA Protein Antibody Vaccination 100

pharmaphorum

APRIL 19, 2022

The funding will be used to continue the clinical development of lead oligonucleotide PGN-EDO51 for DMD, as well as two other oligo drugs PGN-EDODM1 for myotonic dystrophy type 1 (DM1) and PGN-EDO53, another DMD candidate. Once there, they disrupt the expression of RNA coding for disease-associated proteins.

Protein 105

Protein RNA Clinical Development Production 105

Pharmaceutical Technology

DECEMBER 14, 2022

The discovery alliance, with a preliminary research period of four years, will aid GSK in progressing up to eight programmes and Wave to develop up to three programmes. An RNA editing therapy, WVE-006, could act on AATD’s liver and lung manifestations. According to the deal, GSK will make an upfront payment of $170m to Wave.

Life Science 162

Life Science Development Gene Therapy Genetics 162

Pharmaceutical Technology

FEBRUARY 22, 2023

CMN-005 is under clinical development by CoImmune and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). CoImmune is headquartered in Durham, North Carolina, the US. For a complete picture of CMN-005’s drug-specific PTSR and LoA scores, buy the report here.

RNA 100

RNA Development Drugs Clinical Trials 100

BioTech 365

NOVEMBER 18, 2021

Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus (HBV) Program Enanta Pharmaceuticals Announces Update to its Hepatitis B Virus (HBV) Program Discontinuing Clinical Development of EDP-721, an Oral HBV RNA Destabilizer Continuing to Focus on Development of EDP-514 in … Continue reading →

RNA 40

RNA Clinical Development Development 40

pharmaphorum

NOVEMBER 17, 2020

There are 11 potential COVID vaccines in late-stage clinical development and since Pfizer’s announcement two more groups from Russia’s Gamaleya Research Institute and US biotech Moderna have published favourable efficacy results. Pfizer and BioNTech have a $1.95

Vaccination 77

Vaccination Vaccine RNA Clinical Trials 77

pharmaphorum

DECEMBER 7, 2020

China’s Sinovac has raised $515 million to increase its distribution and production capacity as clinical development of its potential coronavirus vaccine nears conclusion. Sinovac has a coronavirus vaccine in late-stage development, which is undergoing large-scale trials in Brazil, Pakistan, Indonesia and Chile.

Vaccination 59

Vaccination Vaccine Production Clinical Development 59

Delveinsight

SEPTEMBER 14, 2021

ADARx bags USD 75 Million to advance its RNA tech pipeline. ADARx Pharmaceuticals, a biotechnology company developing RNA targeting therapeutics , announced the completion of a USD 75 million Series B financing to progress its drug development pipeline. SR One Capital Management and OrbiMed Advisors co-led Series B.

RNA 67

RNA Clinical Trials Clinical Trials Drugs 67

pharmaphorum

FEBRUARY 19, 2021

CEPI has provided early support to Novavax’s effort to develop a COVID vaccine, including the commitment of around $400 million to early clinical development and manufacturing scale-up in several facilities around the globe. The post Novavax provides 1.1 billion COVID shots to global vaccine drive appeared first on.

Vaccination 80

Vaccination Vaccine Manufacturing RNA 80

pharmaphorum

OCTOBER 6, 2020

The vaccine is based on different technology from AZ’s rival: while AZ’s uses a weakened and genetically modified cold virus to prime the immune system, BNT162b2 is based on a string of RNA. According to latest figures from the World Health Organization, there are 42 potential COVID-19 vaccines in clinical development.

Vaccination 59

Vaccination Vaccine RNA Immune Response 59

pharmaphorum

NOVEMBER 18, 2021

The two companies have been working together since 2019 to develop multiple RNA interference (RNAi) candidates for disorders such as non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity and rare diseases. billion in cash. If approved, it could become a $500 million-a-year product, according to the company.

Gene Silencing 52

Gene Silencing RNA Protein Gene 52

Worldwide Clinical Trials

JUNE 15, 2022

Further, some patients are still hesitant to go into the clinic, and the prevalence of misinformation from the pandemic has led to greater concerns about therapies like gene therapies and the impact they fear it will have on their RNA/DNA. The cell and gene therapy pipeline is booming.

Gene Therapy 130

Gene Therapy Gene Clinical Trials Clinical Trials 130

pharmaphorum

NOVEMBER 9, 2020

The phase 3 clinical trial of BNT162b2 began at the end of July and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020. Around 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds.

Vaccination 98

Vaccination Vaccine Clinical Trials Clinical Trials 98

XTalks

JUNE 14, 2023

More Drugs for Dry Eye Disease Are on the Way Several other drugs have recently gained FDA approval or are currently in advanced stages of clinical development for the treatment of dry eye disease. One such approved medication is Miebo , an ophthalmic solution developed by Bausch + Lomb and Novaliq.

Gene Silencing 97

Gene Silencing Drug Delivery FDA Approval RNA 97

XTalks

OCTOBER 26, 2023

She has 23 years of experience working with clients to move vaccine candidates through the clinical development pipeline, including regulatory submission. The Flu versus COVID-19: Virology and Vaccines SARS-CoV-2 versus Influenza Virology Viruses contain genetic material that can either be RNA or DNA.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

pharmaphorum

OCTOBER 16, 2020

There are already three other RNA-based vaccines in trials for COVID-19 from Moderna, Pfizer/BioNTech and CureVac, out of 42 candidates in clinical development, according to the World Health Organization’s latest update. It started human testing of a protein subunit vaccine with partner GlaxoSmithKline last month.

Trials 98

Trials Vaccination Vaccine Antibody 98

The Pharma Data

AUGUST 12, 2020

Moderna continues to rise to meet the demands of the pandemic, signing a new deal with the US Government to supply 100 million doses of its messenger RNA (mRNA) vaccine candidate for the prevention of COVID-19.

Vaccination 52

Vaccination Vaccine Manufacturing RNA 52

The Pharma Data

JUNE 7, 2023

Acuitas’ LNP technology will support Bayer’s in vivo gene editing and protein replacement programs by specifically delivering RNA payloads to the desired target organ, the liver. This delivery technology protects the messenger RNA (mRNA) payload after administration allowing it to be safely and effectively delivered into cells.

Gene Therapy 40

Gene Therapy Gene Gene Editing In-Vivo 40

The Pharma Data

OCTOBER 25, 2020

We are advancing the clinical development of mRNA-1273 with our Phase 3 COVE study, which is now fully enrolled with a representative demography of participants across ages, ethnicities and high-risk populations. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.

Vaccination 52

Vaccination Vaccine Manufacturing Clinical Development 52

XTalks

JANUARY 3, 2024

The collaboration builds upon the companies’ prior work together since March 2022, with Novartis further investing in the research and development of treatments for the neurological disorders​​. Voyager will provide Novartis a target-exclusive license to access Voyager’s TRACER capsids and other intellectual property.

Gene Therapy 52

Gene Therapy Gene Licensing Licensing 52

pharmaphorum

MARCH 29, 2022

We designed BIIB078 to test the prevailing hypothesis that the mechanisms of disease for C9orf72-associated ALS were caused by toxicity associated with the repeat containing RNA and corresponding dipeptides,” said C. Frank Bennett, executive vice president, chief scientific officer and franchise leader for neurological programs at Ionis.

Trials 49

Trials RNA Containment Genetics 49